These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35029045)

  • 1. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
    Vlaar APJ; Lim EHT; de Bruin S; Rückinger S; Pilz K; Brouwer MC; Guo RF; Heunks LMA; Busch MH; van Paassen P; Riedemann NC; van de Beek D
    Clin Transl Sci; 2022 Apr; 15(4):854-858. PubMed ID: 35029045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients.
    Lim EHT; Vlaar APJ; de Bruin S; Rückinger S; Thielert C; Habel M; Guo R; Burnett BP; Dickinson J; Brouwer MC; Riedemann NC; van de Beek D;
    Intensive Care Med Exp; 2023 Jun; 11(1):37. PubMed ID: 37332066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial.
    Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
    Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
    Vlaar APJ; de Bruin S; Busch M; Timmermans SAMEG; van Zeggeren IE; Koning R; Ter Horst L; Bulle EB; van Baarle FEHP; van de Poll MCG; Kemper EM; van der Horst ICC; Schultz MJ; Horn J; Paulus F; Bos LD; Wiersinga WJ; Witzenrath M; Rueckinger S; Pilz K; Brouwer MC; Guo RF; Heunks L; van Paassen P; Riedemann NC; van de Beek D
    Lancet Rheumatol; 2020 Dec; 2(12):e764-e773. PubMed ID: 33015643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
    Bauer M; Weyland A; Marx G; Bloos F; Weber S; Weiler N; Kluge S; Diers A; Simon TP; Lautenschläger I; Gründling M; Jaschinski U; Simon P; Nierhaus A; Moerer O; Reill L; Jörres A; Guo R; Loeffler M; Reinhart K; Riedemann N
    Crit Care Explor; 2021 Nov; 3(11):e0577. PubMed ID: 34806021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Vlaar APJ; Witzenrath M; van Paassen P; Heunks LMA; Mourvillier B; de Bruin S; Lim EHT; Brouwer MC; Tuinman PR; Saraiva JFK; Marx G; Lobo SM; Boldo R; Simon-Campos JA; Cornet AD; Grebenyuk A; Engelbrecht JM; Mukansi M; Jorens PG; Zerbib R; Rückinger S; Pilz K; Guo R; van de Beek D; Riedemann NC;
    Lancet Respir Med; 2022 Dec; 10(12):1137-1146. PubMed ID: 36087611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the use of vilobelimab for the treatment of COVID-19.
    McCarthy MW
    Expert Opin Biol Ther; 2023; 23(9):877-881. PubMed ID: 37421632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.
    van Amstel RBE; Slim MA; Lim EHT; Rückinger S; Seymour CW; Burnett BP; Bos LDJ; van Vught LA; Riedemann NC; van de Beek D; Vlaar APJ;
    Crit Care; 2024 Jun; 28(1):210. PubMed ID: 38943192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in systemic complement component 3a and 5a levels in patients with cerebral arteriovenous malformations.
    Haque R; Hwang BY; Appelboom G; Piazza MA; Guo K; Connolly ES
    J Clin Neurosci; 2011 Sep; 18(9):1235-9. PubMed ID: 21742500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
    Oppermann M; Götze O
    Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anaphylatoxin C3a, C5a on the tubular epithelial-myofibroblast transdifferentiation in vitro.
    Liu F; Gou R; Huang J; Fu P; Chen F; Fan WX; Huang YQ; Zang L; Wu M; Qiu HY; Wei DP
    Chin Med J (Engl); 2011 Dec; 124(23):4039-45. PubMed ID: 22340339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes.
    van Epps DE; Chenoweth DE
    J Immunol; 1984 Jun; 132(6):2862-7. PubMed ID: 6373920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5a and C5a(desArg) enhance the susceptibility of monocyte-derived macrophages to HIV infection.
    Kacani L; Bánki Z; Zwirner J; Schennach H; Bajtay Z; Erdei A; Stoiber H; Dierich MP
    J Immunol; 2001 Mar; 166(5):3410-5. PubMed ID: 11207298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement inhibition in ANCA vasculitis.
    Jayne D
    Nephrol Ther; 2019 Nov; 15(6):409-412. PubMed ID: 31631015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils.
    Elsner J; Oppermann M; Czech W; Dobos G; Schöpf E; Norgauer J; Kapp A
    Eur J Immunol; 1994 Mar; 24(3):518-22. PubMed ID: 8125125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo.
    DiScipio RG; Daffern PJ; Jagels MA; Broide DH; Sriramarao P
    J Immunol; 1999 Jan; 162(2):1127-36. PubMed ID: 9916743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New concepts on the therapeutic control of complement anaphylatoxin receptors.
    Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
    Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.